Medical cannabis is the next frontier of medtech investing, forecasted to become a $35 billion industry by 2020.
How are the challenges of this industry being resolved? Your questions, answered: OurCrowd presents our first investor AMA (“ask me anything”) with medtech advisor, Venture Partner and 25-year industry veteran Dr. Morris Laster.
Below, Dr. Laster addresses medical cannabis, providing answers and insight into the industry as well as the medtech advances made by Syqe Medical, developers of the world’s first meter-dosed botanical inhaler and OurCrowd’s current investment opportunity.
Missed the live AMA? Have more queries about the medical cannabis industry? Don’t let your questions go unanswered!
Leave a comment below and we’ll answer them!
About Dr. Laster
Dr. Laster is a physician with over 25 years of experience in the biopharmaceutical industry and with expertise in identification, development and management of advanced biomedical drugs and technologies. Dr. Laster is the Venture Partner responsible for Medtech investments at OurCrowd; he has founded and/or managed six companies that have gone public in the US, UK and Israel. He invented a novel device to access the circulatory system through the bone marrow, which was approved for development beginning in 2015.